This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–8.
Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transpl. 2017;23:235–46.
Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. Blood. 2020;135:387–91.
Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019;33:2854–66.
Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low dose CD19 directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017;31:2587–93.
Schultz LM, Davis KL, Baggott C, Chaudry C, Marcy AC, Mavroukakis S, et al. Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL). Blood. 2018;132(Suppl 1):898. (abstract 612)
Yang J, Li J, Zhang X, LV F, Guo X, Wang Q, et al. A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia. Blood. 2018;132(Suppl 1):277. (abstract 614)
Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19/22 T-cell “Cocktail” therapy in patients with refractory/relapsed B-Cell malignancies. Blood. 2020;135:17–27.
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552–5.
Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29:3185–93.
Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of B-Cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36:591–9.
Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B -ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–10.
Shah NN. The one-two punch (of CAR T cells). Blood. 2020;135:303–4.
Acknowledgements
This work was supported by the National Key R&D Program of China (2019YFA0110200), the Tianjin Science Funds for Distinguished Young Scholars (17JCJQJC45800), the CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-003; 2017-I2M-1-015), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32034 and 2019-RC-HL-013).
Author information
Authors and Affiliations
Contributions
JP, YT contributed to data collection, data analyses, data interpretation. QZ, HG performed NGS sequencing and analyzed the sequencing data. BD, AHC contributed to CAR T-cell manufacture. JP, CT, ZL, WS, JX, JD, ZW contributed to clinical protocol. XY was responsible for leukemic cell immunophenotyping. JP, YT, LH were responsible for all statistical analyses. The all statistical analyses were in collaboration with biostatisticians from Capital Medical University and eStart Medical Technology CO., Ltd to review raw data and statistical analyses. JP and XF designed and directed the study and wrote the draft of the paper and had final responsibility to submit for publication.
Corresponding authors
Ethics declarations
Conflict of interest
AHC is also a founding member of Shanghai YaKe Biotechnology Ltd. The remaining authors declare no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Pan, J., Tan, Y., Deng, B. et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children. Leukemia 34, 3382–3387 (2020). https://doi.org/10.1038/s41375-020-0831-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0831-z
This article is cited by
-
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Experimental Hematology & Oncology (2024)
-
CAR T-cell behavior and function revealed by real-time imaging
Seminars in Immunopathology (2023)
-
CAR-NK cells for cancer immunotherapy: from bench to bedside
Biomarker Research (2022)
-
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
Signal Transduction and Targeted Therapy (2022)
-
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion
Leukemia (2022)